A carregar cotações...
Previsão
O preço-alvo médio dos analistas é € 23,90 (+5,29%). A mediana é € 22,51 (-0,84%).
| Comprar |
9 |
| Manter |
13 |
| Vender |
2 |
Notícias Ir para o feed de notícias
Doximity falls after downgrade by Freedom Capital
Doximity shares dropped 5.6% after Freedom Capital cut its rating from "buy" to "hold" while raising the price target from $24 to $27. The company reported Q1 results above expectations and raised its revenue outlook but lowered its EBITDA forecast to fund increased investments in AI development and computing power. Freedom Capital reduced its mid-point EBITDA estimate for 2027 from $329 million to $319 million and cited a balanced risk-reward profile for the downgrade; competition from Epic and OpenEvidence and tight pharma budgets remain risks, while AI search contracts are showing early positive momentum. » Mais em de.investing.com
Doximity CEO sells 8,505 shares to cover tax withholding after equity vesting
Doximity CEO Jeffrey Tangney sold 8,505 Class A shares on August 15 to satisfy tax withholding from vested awards, a non-discretionary transaction that reduced his direct stake by roughly 0.3% to 2,531,955 shares (about 1% ownership). The sale does not reflect a market judgment by Tangney and three other insiders had similar withholdings the same day. Company results show slowing top-line growth, margin pressure from rising AI compute costs, and a guidance lull as AI-related revenue recognition is expected later in the year, while the stock has fallen over 60% in the past year. » Mais em finance.yahoo.com
Doximity granted president 150,000 options as he sold small stake to cover taxes
Doximity president Steven L. Zatz sold 4,482 Class A shares in a non‑discretionary sell‑to‑cover to satisfy tax withholding after RSU vesting and retains 51,864 shares (~$1.29m at $24.80). The company granted Zatz 150,000 options on July 22 with a $20.49 strike that begin vesting in July 2027, tying future pay to stock appreciation. Doximity reported Q2 revenue of $156.6m (7% growth) and raised its full‑year range while AI compute costs lowered gross margin to 87.5% and adjusted EBITDA fell 6% to $74.8m; management says higher‑than‑expected AI usage should drive future revenue recognition. Investors should note the option grant links executive upside to stock performance as AI‑related costs and upcoming AI revenue recognition will affect margins and earnings. » Mais em finance.yahoo.com
Dividendos históricos Dividendos
Todos os indicadores de dividendos Todos os indicadoresDados financeiros da empresa
| (EUR) | junho de 2026 | |
|---|---|---|
| Receitas | 137,23 mi | 10,85% |
| Ganho bruto | 116,47 mi | 5,50% |
| Ganho líquido | 21,31 mi | 52,90% |
| EBITDA | 39,12 mi | 31,11% |
Dados fundamentais
| Métrica | Valor |
|---|---|
Capitalização bolsista | € 4,14 bi |
Número de ações | 187,03 mi |
Máximo/mínimo de 52 semanas | € 66,25 - € 14,85 |
| Dividendos | Não |
Beta | 1,25 |
PER (PE Ratio) | 28,74 |
PEG (PEG Ratio) | -1,00 |
P/VC (PB Ratio) | 5,10 |
P/V (PS Ratio) | 7,30 |
Perfil da empresa
Doximity, Inc. betreibt eine Cloud-basierte digitale Plattform für medizinische Fachkräfte in den Vereinigten Staaten. Die Plattform des Unternehmens bietet seinen Mitgliedern Tools, die speziell für Mediziner entwickelt wurden und es ihnen ermöglichen, mit ihren Kollegen zusammenzuarbeiten, die Patientenversorgung zu koordinieren, virtuelle Patientenbesuche durchzuführen, sich über die neuesten medizinischen Nachrichten und Forschungsergebnisse auf dem Laufenden zu halten und ihre Karriere zu verwalten. Das Unternehmen bedient in erster Linie Pharmahersteller und Gesundheitssysteme. Das Unternehmen war früher als 3MD Communications, Inc. bekannt und änderte im Juni 2010 seinen Namen in Doximity, Inc. Doximity, Inc. wurde im Jahr 2010 gegründet und hat seinen Hauptsitz in San Francisco, Kalifornien.
| Nome | DOXIMITY INC DL-,001 |
| CEO | Jeffrey A. Tangney |
| Sede | San Francisco,
ca EUA |
| Site | |
| Setor | Cuidados de saúde |
| Indústria | Tecnologia de saúde |
| Entrada em bolsa | 02/01/2008 |
| Colaboradores | 880 |
Análise aprofundada
Símbolos de ticker
| Bolsa | Símbolo |
|---|---|
NYSE | DOCS |